Premium
Transfusion‐associated graft vs. host disease in a patient with high‐grade B‐cell lymphoma. Should cellular products for patients with non‐Hodgkin's lymphoma be irradiated?
Author(s) -
Gelly K. J.,
Kerr R.,
Rawlinson S.,
Norris A.,
Bowen D. T.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02176.x
Subject(s) - lymphoma , medicine , disease , hodgkin lymphoma , graft versus host disease , blood transfusion , hematology , blood product , gastroenterology , immunology , oncology , surgery
We present the case of a 64‐year‐old man who died from transfusion‐associated graft vs. host disease (TA‐GVHD) having been treated 2 years earlier for a high‐grade, non‐Hodgkin's lymphoma (NHL). We suggest that he was at increased risk of developing TA‐GVHD as a result of the NHL and its subsequent treatment, and propose that patients with NHL should be added to those ‘at risk’ groups who receive irradiated cellular blood components.